WST

250.49

2.82% 6.88

Dopo l'orario di chiusura: 250.49

West Pharmaceutical Services Inc (WST)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché WST Giù? Forum Previsione Frazionamento azionario Storia dei dividendi

Precedente Chiudi:

$243.61

Aprire:

$243.94

Volume 24 ore:

978.09K

Relative Volume:

1.14

Capitalizzazione di mercato:

$18.02B

Reddito:

$2.96B

Utile/perdita netta:

$487.70M

Rapporto P/E:

37.52

EPS:

6.6758

Flusso di cassa netto:

$344.00M

1 W Prestazione:

+0.62%

1M Prestazione:

-7.85%

6M Prestazione:

+1.73%

1 anno Prestazione:

+25.80%

Intervallo 1D:

$242.14

$250.53

Intervallo di 1 settimana:

$227.49

$259.90

Portata 52W:

$187.43

$322.34

West Pharmaceutical Services Inc Stock (WST) Company Profile

Nome

West Pharmaceutical Services Inc

Settore

Healthcare (1111)

Industria

Medical Instruments & Supplies (58)

Telefono

(610) 594-2900

Indirizzo

530 HERMAN O. WEST DRIVE, EXTON, PA

Dipendente

10,600

Cinguettio

@WestPharma

Prossima data di guadagno

2024-10-24

Ultimi documenti SEC

WST's Discussions on Twitter

Compare WST vs ISRG, BDX, ALC, MDLN, RMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
WST West Pharmaceutical Services Inc	250.49	17.53B	2.96B	487.70M	344.00M	6.6758
ISRG Intuitive Surgical Inc	485.84	169.97B	10.06B	2.88B	2.49B	7.876
BDX Becton Dickinson Co	175.89	50.58B	21.92B	1.76B	2.63B	6.1223
ALC Alcon Inc	79.20	38.58B	10.19B	1.05B	1.38B	2.1044
MDLN Medline Inc	44.55	37.11B	27.43B	1.27B	1.01B	1.5829
RMD Resmed Inc	252.55	35.80B	5.40B	1.49B	1.78B	10.12

West Pharmaceutical Services Inc Stock (WST) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-12-02	Iniziato	Morgan Stanley	Equal-Weight
2025-09-15	Iniziato	Rothschild & Co Redburn	Buy
2025-06-24	Iniziato	Barclays	Equal Weight
2025-03-18	Iniziato	Evercore ISI	Outperform
2025-02-14	Aggiornamento	Deutsche Bank	Hold → Buy
2025-01-08	Iniziato	Citigroup	Buy
2024-12-13	Iniziato	Wolfe Research	Peer Perform
2024-12-12	Aggiornamento	UBS	Neutral → Buy
2024-02-07	Aggiornamento	Jefferies	Hold → Buy
2023-06-16	Aggiornamento	BofA Securities	Neutral → Buy
2023-04-11	Aggiornamento	Stephens	Equal-Weight → Overweight
2022-12-14	Iniziato	Deutsche Bank	Hold
2022-11-30	Iniziato	UBS	Neutral
2022-10-28	Downgrade	BofA Securities	Buy → Neutral
2020-11-10	Iniziato	KeyBanc Capital Markets	Overweight
2020-10-14	Iniziato	Stephens	Equal-Weight
2020-07-21	Aggiornamento	BofA Securities	Neutral → Buy
2020-04-24	Aggiornamento	BofA/Merrill	Underperform → Neutral
2019-12-12	Downgrade	BofA/Merrill	Neutral → Underperform
2019-07-26	Aggiornamento	BofA/Merrill	Underperform → Neutral
2019-05-01	Downgrade	Jefferies	Buy → Hold
2019-04-23	Iniziato	William Blair	Outperform
2018-04-25	Downgrade	BofA/Merrill	Neutral → Underperform
2018-01-24	Iniziato	Goldman	Neutral
2017-10-17	Downgrade	BofA/Merrill	Buy → Neutral
2017-10-03	Iniziato	Stephens	Equal-Weight
2017-09-15	Aggiornamento	Jefferies	Hold → Buy
2016-10-28	Aggiornamento	Wells Fargo	Market Perform → Outperform
2016-09-21	Downgrade	Wells Fargo	Outperform → Market Perform
2016-03-22	Iniziato	Wells Fargo	Outperform
2010-05-14	Reiterato	UBS	Neutral
2010-02-23	Iniziato	Jefferies & Co	Buy
2008-12-19	Iniziato	UBS	Neutral

Mostra tutto

West Pharmaceutical Services Inc Borsa (WST) Ultime notizie

Feb 13, 2026

West Pharmaceutical Services (WST): Barclays Lowers Price Target - GuruFocus

Feb 13, 2026

West Pharmaceutical Services, Inc. (NYSE:WST) Q4 2025 Earnings Call Transcript - Insider Monkey

Feb 13, 2026

West Pharmaceutical Services Q4 Earnings Call Highlights - Yahoo Finance

Feb 13, 2026

West Pharmaceutical targets 5%–7% organic revenue growth for 2026 as HVP demand accelerates - MSN

Feb 13, 2026

Feb 12, 2026

West Pharma forecasts 2026 profit above estimates on strong demand for drug components - 104.1 WIKY

Feb 12, 2026

Earnings call transcript: West Pharmaceutical Services Q4 2025 earnings beat expectations - Investing.com Canada

Feb 12, 2026

West Pharmaceutical Services (WST) Is Up 5.2% After Strong 2025 Results And 2026 Organic Growth Outlook - Yahoo Finance

Feb 12, 2026

West Pharmaceutical Q4 2025 slides: Revenue up 7.5%, EPS exceeds expectations - Investing.com Nigeria

Feb 12, 2026

West Pharmaceutical Services (NYSE:WST) Issues Quarterly Earnings Results, Beats Expectations By $0.21 EPS - MarketBeat

Feb 12, 2026

West Pharmaceutical Services's (NYSE:WST) Q4 CY2025: Beats On Revenue, Stock Soars - Finviz

Feb 12, 2026

WST's Q4 Earnings & Sales Beat, SmartDose Sale by Mid-2026, Stock Up - Finviz

Feb 12, 2026

Iron Mountain Projects Double-Digit Growth in 2026 - Investing.com

Feb 12, 2026

West Pharmaceutical Q4 2025 slides: Revenue up 7.5%, EPS exceeds expectations By Investing.com - Investing.com India

Feb 12, 2026

West Pharmaceutical (WST) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance

Feb 12, 2026

West Pharmaceutical Services (NYSE:WST) Issues FY 2026 Earnings Guidance - MarketBeat

Feb 12, 2026

In the latest conference call, West Pharmaceutical Services Inc executives noted that although demand for GLP-1 drugs is showing strong growth momentum in 2025, the growth pace is expected to slow down in 2026. - Bitget

Feb 12, 2026

West Pharmaceutical (WST) Exceeds Market Expectations with Stron - GuruFocus

Feb 12, 2026